Breaking News

Evotec, Sandoz Announce Potential Sale of Just – Evotec Biologics EU 

Planned deal terms include the purchase price of the Toulouse site for approximately $300 million in cash.

Evotec SE has signed a non-binding agreement with Sandoz AG regarding the potential sale of Just – Evotec Biologics EU, which owns the J.POD biologics manufacturing facility in Toulouse, France, and to grant access to its platform for integrated development and advanced continuous manufacturing of biologics via a technology license. The site has been customized and dedicated entirely to Sandoz since July 2024, and the transaction aims to advance the partnership. Closing of the planned transac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters